Open AI has just announced how to create a GPT agent. In the realm of healthcare, understanding and addressing patient adherence is crucial for successful treatment outcomes. Health care providers have an invaluable tool in the Morisky Medication Adherence Scale (MMAS-8) to identify intentional non-adherence among patients.
The MMAS-8 is a self-report measure that assesses a patient's adherence to medications. It delves into the patient's behavior, identifying intentional non-adherence – instances where patients consciously decide not to adhere to prescribed treatments. By utilizing this scale, healthcare providers can pinpoint areas of concern and tailor interventions to improve adherence.
Once the GPT agent identifies intentional non-adherence which is often multifaceted. Mental health plays a pivotal role, and depression can significantly impact a patient's ability to adhere to medical recommendations. Enter the Collaborative Study of Depression (CUDOS) scale, a reliable instrument for assessing depression.
The GPT agent can strategically implement the CUDOS scale to explore the potential link between depression and non-adherence. By identifying depressive symptoms, providers gain insights into the patient's mental health, recognizing a crucial dimension of adherence that extends beyond the physical aspect.
The GPT agent then can target motivational interviewing questions from the patient-related dimension of non-adherence. Depression can manifest as a barrier to following prescribed treatments, with symptoms like fatigue, lack of motivation, and diminished interest in activities contributing to intentional non-adherence. Recognizing this interplay between mental health and adherence is pivotal for a holistic approach to patient care.
Dr Donald Morisky.